Sarissa Capital Management LP
Position in NBIX — Neurocrine Biosciences Inc
CIK 1577524
GREENWICH, CT
Position in NBIX
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$19,640,471
+$4,288,414 QoQ
Shares Held
116,533
0.0% QoQ
Ownership
0.115%
of shares outstanding
% of Portfolio
11.04%
of 13F equity value
Holder Rank
#112
of 772 holders
Holding Since
Jun 2023
13 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NBIX Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Sarissa Capital Management LP holds $76,842,617 across 3 Drug Manufacturers - Specialty & Generic names. NBIX ranks #2 (25.6% of the industry book) .
All Filings in NBIX
Export CSV
13 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $19,640,471 | 116,533 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $15,352,057 | 116,533 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $42,995,906 | 303,151 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $42,556,337 | 303,151 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $38,103,049 | 303,151 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $34,188,229 | 309,116 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $42,194,334 | 309,116 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $47,295,851 | 410,483 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $56,511,194 | 410,483 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $47,779,073 | 346,426 | Shares | Sole | 2024-05-15 | |
| 2023-12-31 | $61,927,200 | 470,000 | Shares | Sole | 2024-02-14 | |
| 2023-09-30 | $41,175,000 | 366,000 | Shares | Sole | 2023-11-14 | |
| 2023-06-30 | $21,811,590 | 231,300 | Shares | Sole | 2023-08-14 | |
| No filing history on record for this holder in this stock. | ||||||